What You Need To Know About Medicare Part B Step Therapy: AMCP Nexus 2022
Yuqian Liu, Pharm.D., and Michelle Booth, Pharm.D., of Magellan Rx Management, discuss the background and consequences of step therapy in Medicare Part B in an interview prior to their session at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
This interview was recorded prior to the meeting.
CMS has estimated that step therapy for Part B drugs in Medicare Advantage plans could save the Medicare program over $1.9 billion from 2020 to 2029 years, according to Yuqian Liu, Pharm.D., senior director of specialty clinical solutions at Magellan Rx Management.
Liu said CMS has estimated that step therapy will save beneficiaries about $62 million in out-of-pocket costs during the same period.
Liu and her colleague, Michelle Booth, spoke to Managed Healthcare Executive® prior to their presentation about Part B step therapy in Medicare Advantages scheduled for today at AMCP Nexus 2022 meeting in National Harbor, Maryland.
Michelle Booth, Pharm.D., also a senior director of specialty clinical solutions at Magellan, said most plans were cautious about jumping into step therapy.
"A lot of folks started small (with step therapy) and then expanded based on where their utilization was and where they kind of felt like the biggest bang for their buck was," Booth told Managed Healthcare Executive®.
Cost savings for the plans were quite high from the program at first , then decreased after the first year. However, Booth feels savings have been "fairly stable."
Booth also noted that some time and effort went into developing care coordination programs that CMS had indicated would be required but then changed course and decided not to require them.
Addressing the Challenges of AI is Imperative | AMCP Nexus 2024
October 22nd 2024There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
AI Benefits PBMs, Health Plans and Formulary Decision Making | AMCP Nexus 2024
October 21st 2024Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
Read More
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
Read More
How Technology Benefits Specialty Pharmacy | AMCP 2024
October 18th 2024Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research, explains how technology identifies at-risk patients, coordinates medication refills and more.
Read More
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
